Under U.S. GAAP, acquired IPR&D accounting works like this: when one company buys another that has unfinished research and development projects, the acquirer records those projects at fair value on the acquisition date and carries them as indefinite-lived intangible assets. No amortization runs while development continues. The asset sits on the balance sheet, gets tested for impairment each year, and is only reclassified once the project either reaches completion or is abandoned. This treatment is deliberately different from how a company accounts for R&D it runs itself, and the mechanics matter for goodwill, future earnings, and deal comparability.
What Qualifies as Acquired IPR&D
Acquired IPR&D covers projects still actively under development on the acquisition date. A pharmaceutical candidate in clinical trials, a semiconductor design not yet out of the lab, an unreleased software product: the common thread is that the technical work isn’t finished and the outcome isn’t certain.
For the project to be recognized separately from goodwill, it has to qualify as an identifiable intangible asset under ASC 805. That means meeting at least one of two criteria: the asset is separable (it could be sold, licensed, or transferred on its own) or it arises from contractual or legal rights, such as a patent application or licensing agreement.1Deloitte. Roadmap Business Combinations – 4.10 Intangible Assets If a project fails both tests, its value stays inside goodwill.
The reason the accounting works at all is the acquisition itself. A negotiated arm’s-length price gives the market’s read on each developing project. That external signal is what internally generated R&D lacks, and it’s why acquired IPR&D can be capitalized while a company’s own R&D generally can’t.
Fair Value at the Acquisition Date
Every identifiable asset acquired and liability assumed is measured at fair value during the purchase price allocation. For IPR&D, that means carving out the value of each developing project rather than defaulting it into goodwill.
Because IPR&D assets rarely trade in active markets, valuation specialists use the income approach, which discounts projected future cash flows to present value.2Accounting Today. AICPA Issues Accounting and Valuation Guide for IPR&D The most common technique is the multi-period excess earnings method (MEEM). The analyst projects cash flows over the product’s expected commercial life assuming successful completion, subtracts charges for contributory assets that help generate those revenues (working capital, fixed assets, existing technology), and discounts the residual back to present value.
Two inputs make the answer highly sensitive to judgment. The first is probability of success, which reduces projected cash flows to reflect the risk that the project never reaches the market. A late-stage pharmaceutical compound with Phase III data might carry a probability around 80%; an early-stage platform technology could sit below 30%. The second is the discount rate. Unproven projects carry more risk than established revenue lines, so the rate applied to IPR&D cash flows runs meaningfully higher than the acquirer’s overall cost of capital. Small shifts in either input move the value substantially, which is why independent third-party valuation experts are nearly always brought in.
Whatever value comes out of that exercise is capitalized on the acquirer’s balance sheet and becomes the starting point for everything that follows.
Measurement Period Adjustments
Purchase price allocations often start out provisional, particularly for something as judgment-heavy as IPR&D. ASC 805 gives the acquirer a measurement period to refine those provisional amounts as new information emerges about facts that existed on the acquisition date. The period ends once the acquirer has the information it was seeking and cannot run longer than one year from the acquisition date.3Deloitte. Roadmap Business Combinations – 6.1 Measurement Period
If the acquirer later learns the project was further along or less advanced than first estimated, the provisional fair value is adjusted with an offsetting change to goodwill. The revised accounting is treated as if it had been applied from the acquisition date, so any catch-up effects on depreciation, amortization, or other income items are recognized in the current period.
What Happens After the Deal Closes
Once the IPR&D asset is on the books, its path splits based on whether the underlying project succeeds or fails.
If the Project Succeeds
When the R&D work is complete, the asset is reclassified from indefinite-lived to finite-lived. What counts as completion depends on the industry: regulatory approval to market the product for a pharmaceutical company, readiness for commercial release for a technology company.4U.S. Securities and Exchange Commission. SEC EDGAR Filing – Intangible Assets Disclosure
From that point, the asset is amortized over its estimated useful life, which is the period it’s expected to contribute to future cash flows. Straight-line amortization is standard. The expense reduces reported earnings each period, and management should reassess the remaining useful life periodically and adjust prospectively if conditions change. A required impairment test runs at the reclassification date before amortization begins.
If the Project Fails or Is Abandoned
If the project fails, or management decides to stop pursuing it, the carrying value is written down and the write-off is recorded as an impairment loss on the income statement. One nuance from the AICPA guidance: assets tied to abandoned projects should be evaluated for whether they still serve a defensive purpose that protects or enhances other assets. A company might halt active development but keep a patent to block competitors from using the technology, and in that case the asset wouldn’t necessarily be written down to zero.
Annual Impairment Testing During Development
While IPR&D remains in development, it isn’t amortized. Instead, ASC 350 requires an impairment test at least once a year.5Deloitte. 4.4 Intangible Assets Not Subject to Amortization More frequent testing is required when triggering events occur, such as a failed clinical trial, a competitive shift, or a significant budget cut for the project.
A company can perform a qualitative “Step 0” assessment first, evaluating whether it’s more likely than not (greater than 50% probability) that the asset is impaired. If the qualitative review concludes impairment is unlikely, no further work is needed. If it points the other way, the company calculates the asset’s current fair value; when carrying value exceeds fair value, the difference is recognized as an impairment loss.
Business Combination vs. Asset Acquisition
Everything above applies when the buyer obtains control of an actual business. If the transaction is instead an asset acquisition, meaning the group of assets doesn’t constitute a business, the accounting flips.
In an asset acquisition, IPR&D with no alternative future use must be expensed immediately under ASC 730, the same way internal R&D is treated. Only IPR&D that has an alternative future use, meaning it could be redeployed on other projects if the current one fails, can be capitalized.6Deloitte. Roadmap Business Combinations – C.3 Allocating the Cost in an Asset Acquisition Two identical projects can end up with completely different treatments depending on the deal structure: acquire the drug candidate through an asset purchase and the cost hits the income statement on day one; acquire the same candidate by buying the business that developed it and the cost sits on the balance sheet as an indefinite-lived intangible.
Why This Differs from Internal R&D
Under ASC 730, R&D costs a company incurs on its own projects are expensed as incurred.7FASB. Research and Development (Topic 730) – Proposed ASU There’s no capitalization option, no matter how promising the work looks. The rationale is measurement reliability: without an arm’s-length transaction, the link between lab spending and future revenue is too speculative to support recognition. Acquired IPR&D clears that hurdle because the acquisition price provides the external anchor.
The practical result is that two companies with similar pipelines can look very different on the balance sheet depending on whether they built or bought.
IFRS and Tax Notes
For IPR&D acquired in a business combination, IFRS reporters follow a broadly similar path. IFRS 3 requires identifiable intangible assets to be recognized separately from goodwill under the same separability or contractual-legal criterion used in U.S. GAAP.8IFRS Foundation. IFRS 3 Business Combinations The larger divergence is on internal R&D: IAS 38 separates a research phase (always expensed) from a development phase (capitalized when technical feasibility, intent to complete, ability to use or sell, probable future benefits, resources, and reliable measurement are all demonstrated). When comparing companies across frameworks, that difference on internal development spending often matters more than anything about acquired IPR&D itself.
On the tax side, GAAP and the Internal Revenue Code have long produced timing differences for R&D. Since 2022, Section 174 required companies to capitalize and amortize R&D expenditures over five years for domestic research and fifteen years for foreign research. The One Big Beautiful Bill Act reversed the domestic piece: under new Section 174A, domestic research and experimental expenditures are again immediately deductible for tax years beginning after December 31, 2024. Foreign research still has to be capitalized and amortized over fifteen years. For acquired IPR&D, the indefinite-lived GAAP treatment and the tax treatment will typically generate deferred tax assets or liabilities, and the interaction with goodwill and the current Section 174 rules is worth close coordination between accounting and tax teams.